Shahabul Arfeen, MD
Nephrology · Michigan City, INNPI 1538164140
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,109 of the $4,027 with a category attached, or 77.2%. 14 manufacturers reported payments, led by AstraZeneca at 37.5% of the total. Reporting peaked in 2021 at $890 and has fallen 59.7% since, to $358 in 2025.
Across 142 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$375
- Vifor Pharma, Inc.$365
- Baxter Healthcare$345
- Travere Therapeutics, Inc.$295
- Fresenius USA Marketing, Inc.$261
- plus $875 from 8 others
Across 88 payments — averaging $1724.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$150K
- Janssen Research & Development, LLC$2K
What the payments were for
- Consulting fees$3459%
- Speaking & faculty fees$40010%
- Food & beverage$3,10977%
- Education$1734%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 47 | $1,512 |
| Amgen(2 entities) | 16 | $375 |
| Vifor Pharma, Inc. | 18 | $365 |
| Baxter Healthcare | 1 | $345 |
| Travere Therapeutics, Inc. | 9 | $295 |
| Fresenius USA Marketing, Inc. | 9 | $261 |
| Otsuka America Pharmaceutical, Inc. | 11 | $234 |
| GSK | 12 | $199 |
| Novo Nordisk | 6 | $152 |
| Aurinia Pharma U.S., Inc. | 5 | $132 |
| OPKO Pharmaceuticals, LLC | 3 | $52 |
| Calliditas Therapeutics US Inc. | 2 | $45 |
| Johnson & Johnson | 2 | $31 |
| Bayer | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - CRRT$345
- SOLIRIS$150
How this compares
$4,027 in reported general payments places this provider in the 75th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $55,017 |
| FarxigaDapagliflozin Propanediol | 58 | $50,612 |
| TrulicityDulaglutide | 30 | $38,715 |
| RybelsusSemaglutide | 24 | $35,960 |
| JardianceEmpagliflozin | 22 | $22,685 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $11,629 |
| EntrestoSacubitril/Valsartan | 16 | $10,815 |
| EliquisApixaban | 16 | $4,815 |
| Calcium Acetate | 47 | $2,657 |
| Febuxostat | 11 | $1,374 |
| Colchicine | 14 | $1,136 |
| Salsalate | 21 | $1,116 |
| Sevelamer Carbonate | 15 | $1,066 |
| Lisinopril | 144 | $834 |
| Furosemide | 128 | $754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $152 | $90,97766 claims |
| AstraZenecaFarxiga, Lokelma | $1,512 | $62,24173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 238 nephrology providers in Indiana.
Other nephrology in Michigan City
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Narothama Reddy AeddulaEvansville$125K
- Gaurav VermaTerre Haute$125K
- Manish GeraTerre Haute$113K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Jorge DiegoShelbyville$81K
- Muhammad MujtabaIndianapolis$71K
- Andrew OshaughnessyFort Wayne$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.